Phio Pharmaceuticals Corp
PHIO2.320USD
-0.010-0.43%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
11.09MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Phio Pharmaceuticals Corp Unternehmen
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Unternehmensinformationen
BörsenkürzelPHIO
Name des UnternehmensPhio Pharmaceuticals Corp
IPO-datumMay 10, 2012
CEOMr. Robert J. Bitterman
Anzahl der mitarbeiter5
WertpapierartOrdinary Share
GeschäftsjahresendeMay 10
Addresse411 Swedeland Road
StadtKING OF PRUSSIA
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl19406
Telefon15087673861
Websitehttps://phiopharma.com/
BörsenkürzelPHIO
IPO-datumMay 10, 2012
CEOMr. Robert J. Bitterman
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
27.15K
+168.32%
Mr. Robert L. Ferrara, CPA
Mr. Robert L. Ferrara, CPA
Lead Independent Director
Lead Independent Director
15.67K
+176.49%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
356.00
--
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
--
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Dr. Jonathan E Freeman, Ph.D.
Dr. Jonathan E Freeman, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lisa Carson
Ms. Lisa Carson
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
27.15K
+168.32%
Mr. Robert L. Ferrara, CPA
Mr. Robert L. Ferrara, CPA
Lead Independent Director
Lead Independent Director
15.67K
+176.49%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
356.00
--
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
--
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Dr. Jonathan E Freeman, Ph.D.
Dr. Jonathan E Freeman, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Orca Capital GmbH
10.73%
Heights Capital Management, Inc.
1.90%
Macquarie Investment Management
1.04%
The Vanguard Group, Inc.
1.01%
Geode Capital Management, L.L.C.
0.87%
Other
84.45%
Aktionäre
Aktionäre
Anteil
Orca Capital GmbH
10.73%
Heights Capital Management, Inc.
1.90%
Macquarie Investment Management
1.04%
The Vanguard Group, Inc.
1.01%
Geode Capital Management, L.L.C.
0.87%
Other
84.45%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
15.61%
Investment Advisor/Hedge Fund
0.87%
Individual Investor
0.60%
Venture Capital
0.23%
Hedge Fund
0.05%
Research Firm
0.02%
Other
82.61%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
36
834.27K
17.39%
+508.13K
2025Q1
36
775.62K
16.17%
+505.98K
2024Q4
32
296.95K
9.15%
+222.42K
2024Q3
32
80.42K
6.72%
+23.30K
2024Q2
31
23.09K
4.32%
-37.39K
2024Q1
33
20.92K
3.89%
-41.19K
2023Q4
35
59.17K
22.55%
+23.31K
2023Q3
40
35.14K
14.50%
-1.09K
2023Q2
42
33.69K
17.19%
+22.39K
2023Q1
44
7.53K
5.91%
-5.09K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Orca Capital GmbH
514.97K
10.73%
+514.97K
--
Jan 17, 2025
Heights Capital Management, Inc.
90.99K
1.9%
+90.99K
--
Dec 31, 2024
Macquarie Investment Management
50.00K
1.04%
--
--
Apr 30, 2025
The Vanguard Group, Inc.
48.66K
1.01%
--
--
May 31, 2025
Geode Capital Management, L.L.C.
41.59K
0.87%
+41.59K
--
Mar 31, 2025
Cetera Investment Advisers LLC
38.50K
0.8%
+25.50K
+196.15%
Mar 31, 2025
Bitterman (Robert J)
10.12K
0.21%
+3.50K
+52.89%
Jun 10, 2025
Ferrara (Robert L)
5.67K
0.12%
+2.50K
+78.96%
Jun 10, 2025
Infarinato (Robert M. Esq., CPA)
11.00K
0.23%
+3.00K
+37.50%
Sep 11, 2024
XTX Markets LLC
10.80K
0.23%
+10.80K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jan 25, 2023
Merger
12<1
Jan 25, 2023
Merger
12<1
Datum
Art
Verhältnis
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jan 25, 2023
Merger
12<1
Jan 25, 2023
Merger
12<1
Jan 25, 2023
Merger
12<1
Jan 25, 2023
Merger
12<1
